Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
Open accessThe DOI matches its Crossref record; 205 of the 210 references it cites were found in a registry or an index.
Abstract
Approximately 90% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). PDAC is the fourth leading cause of cancer death world-wide. Therapies for PDAC are largely ineffective due to the dense desmoplastic tumor microenvironment which prevents chemotherapeutic drugs and small molecule inhibitors from exerting effective anti-cancer effects. In this review, we will discuss the roles of TP53 and miRs on the PDAC tumor microenvironment and how loss of the normal functions of TP53 promote tumor progression. The TP53 gene is mutated in approximately 50% of pancreatic cancers. Often, these TP53 mutations are point mutations which confer additional functions for the TP53 proteins. These are called gain of function (GOF) mutations (mut). Another class of TP53 mutations are deletions which result in loss of the TP53 protein; these are referred to TP53-null mutations. We have organized this review into various components/properties of the PDAC microenvironment and how they may be altered in the presence of mutant TP53 and loss of certain miR expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 mutations, found in 50–90% of pancreatic ductal adenocarcinomas, significantly affect carcinogenesis, prognosis and treatment response [17,21,34,35].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutations, particularly gain-of-function (GOF) variants, alter the tumor microenvironment, promoting proliferation and chemotherapy resistance [34,36].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“TP53’s multifaceted role extends to metabolic regulation, shaping the hostile PDAC microenvironment by influencing metabolic reprogramming, autophagy and ferroptosis [34].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Huang, F., Chen, W., Peng, J., Li, Y., Zhuang, Y., Zhu, Z., Shao, C., Yang, W., Yao, H., & Zhang, S. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0845-6 · Cited by 134 · cited 2×
“Various miRs and LncRNAs are involved in the regulation of autophagy; these include miR-506 [145], miR-372 [146] and LncRNA PVT1 [147].”
BackgroundRetractedNF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679 · cited 1×
“Increased IL-6 expression is associated with metastasis [12].”
BackgroundDistinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
(1999) · PubMed · Cited by 2,204
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 2,157
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970 · cited 1×
“YAP can induce the reprogramming of cancer cells into cancer stem cells in some models [88].”
BackgroundKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
The role of ROS in tumour development and progression
Cheung, E. C., & Vousden, K. H. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00435-0 · Cited by 1,595
Inflammation meets cancer, with NF-κB as the matchmaker
Ben-Neriah, Y., & Karin, M. (2011) · Nature Immunology · doi:10.1038/ni.2060 · Cited by 1,373 · cited 2×
“These mutations can contribute to elevated levels of the NF-κB signaling which regulates expression of many inflammatory cytokines, including IL-6, IL8 and IL-18 [70].”
BackgroundHallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990 · cited 1×
“This results in PDAC remodeling of the microenvironment and progression of the PanIN and the ability of immune cells to infiltrate the PDAC microenvironment [4].”
BackgroundHypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Covello, K. L., Kehler, J., Yu, H., Gordan, J. D., Arsham, A. M., Hu, C.-J., Labosky, P. A., Simon, M. C., & Keith, B. (2006) · Genes & Development · doi:10.1101/gad.1399906 · Cited by 821 · cited 1×
“Octamer-binding transcription factor 4 (Oct-4) is a transcription factor that has been observed to be induced in cancer cells under hypoxic conditions [102,103].”
BackgroundRegulation of glut1 mRNA by Hypoxia-inducible Factor-1
Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., & Maity, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010144200 · Cited by 771 · cited 3×
“HIF-1α also increases GLUT-1 levels [128] as well the expression of glycolysis-related genes [129].”
BackgroundKRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744 · cited 1×
“YAP has been shown to promote keys events in KRas-mediated pancreatic cancer tumorigenesis, namely: growth, drug resistance, metabolic reprogramming, differentiation, EMT and metastasis [83,84].”
BackgroundRole of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721 · cited 1×
“The KRAS mutations result in the constitutive activation of a critical GTP/GDP GTPase exchange protein which is an important regulator (on/off switch) in multiple signal transduction pathways [2].”
Backgroundp53 status determines the role of autophagy in pancreatic tumour development
Rosenfeldt, M. T., O’Prey, J., Morton, J. P., Nixon, C., MacKay, G., Mrowinska, A., Au, A., Rai, T. S., Zheng, L., Ridgway, R., et al. (2013) · Nature · doi:10.1038/nature12865 · Cited by 713
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Bryant, K. L., Stalnecker, C. A., Zeitouni, D., Klomp, J. E., Peng, S., Tikunov, A. P., Gunda, V., Pierobon, M., Waters, A. M., George, S. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0368-8 · Cited by 692 · cited 1×
“Recently, it was shown that combining chloroquine with a MEK inhibitor was very effective in suppressing PDAC growth [178].”
Backgroundp53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation
Kawauchi, K., Araki, K., Tobiume, K., & Tanaka, N. (2008) · Nature Cell Biology · doi:10.1038/ncb1724 · Cited by 637 · cited 3×
“Abbreviations: transforming growth factor-β (TGF-β), small mothers against decapentaplegic ho- molog 4 protein (SMAD4), small mothers against decapentaplegic homolog 3 protein (SMAD3), small mothers against decapentaplegic homolog 2 protein (SMAD2), Kruppel-like factor 4 (KLF4), Kru pel-like factor 2 (KLF2), cyclin- e…”
BackgroundThe role of TGF-β/SMAD4 signaling in cancer
Zhao, M., Mishra, L., & Deng, C.-X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23230 · Cited by 631 · cited 10×
“The SMAD4 gene encodes a transcription factor, and it is downstream of TGF-β [17].”
BackgroundInfluentialKRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617
Dai, E., Han, L., Liu, J., Xie, Y., Kroemer, G., Klionsky, D. J., Zeh, H. J., Kang, R., Wang, J., & Tang, D. (2020) · Autophagy · doi:10.1080/15548627.2020.1714209 · Cited by 613
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610 · cited 6×
“Cells 2022, 11, 2155. https://doi.org/10.3390/cells11142155 https://www.mdpi.com/journal/cells KRAS is mutated in >95% of PDACs.”
BackgroundInfluentialp53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2
Kim, T., Veronese, A., Pichiorri, F., Lee, T. J., Jeon, Y.-J., Volinia, S., Pineau, P., Marchio, A., Palatini, J., Suh, S.-S., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110235 · Cited by 514 · cited 1×
“TP53 can also modulate the expression of miR-200, which in turn regulates the expression of transcription factors such as ZEB1 and ZEB2 which promote EMT in certain cell types such as hepatocellular carcinoma [58].”
BackgroundTargeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
Mlecnik, B., Bindea, G., Kirilovsky, A., Angell, H. K., Obenauf, A. C., Tosolini, M., Church, S. E., Maby, P., Vasaturo, A., Angelova, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6352 · Cited by 472 · cited 1×
“Likewise, primary pancreatic cancers can modulate the tumor microenvironment by secreting various factors in exosomes which favor colonization in metastatic sites [27].”
BackgroundCooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.022 · Cited by 466 · cited 1×
“Mut-TP53 can also induce NF-κB activity, which in turn induces inflammatory cytokine expression, including IL-6 and tumor necrosis factor-α (TNF-α), and promotes metastasis [13].”
BackgroundMutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466 · cited 1×
“GOF-TP53 mutations result in a fibrotic tumor microenvironment [63].”
BackgroundEprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes
Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465 · cited 1×
“patients who have mut-TP53 in combination with azacitidine, a nucleoside analog which has previously been used to treat MDS patients [202].”
Backgroundp53 Represses the Mevalonate Pathway to Mediate Tumor Suppression
Moon, S.-H., Huang, C.-H., Houlihan, S. L., Regunath, K., Freed-Pastor, W. A., Morris, J. P., Tschaharganeh, D. F., Kastenhuber, E. R., Barsotti, A. M., Culp-Hill, R., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.011 · Cited by 435 · cited 1×
“WT-TP53 has been shown to suppress the MVA pathway in mouse models of liver cancer [137].”
BackgroundTumour-associated mutant p53 drives the Warburg effect
Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434 · cited 1×
“MutTP53 can increase the expression of GLUT-1 by inducing its translocation to the plasma membrane [127].”
BackgroundParkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect
Zhang, C., Lin, M., Wu, R., Wang, X., Yang, B., Levine, A. J., Hu, W., & Feng, Z. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113884108 · Cited by 431 · cited 1×
“TP53 can induce PARKIN gene expression which affects glucose metabolism and inhibits breast cancer progression [117,118].”
BackgroundP53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis
Yamakuchi, M., Lotterman, C. D., Bao, C., Hruban, R. H., Karim, B., Mendell, J. T., Huso, D., & Lowenstein, C. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911082107 · Cited by 430 · cited 1×
“This will prevent the formation of HIF-1α/HIF-1β heterodimers and suppresses angiogenesis of colorectal cancer [120].”
BackgroundThe role of hypoxia-inducible factors in metabolic diseases
Gonzalez, F. J., Xie, C., & Jiang, C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0096-z · Cited by 407
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 392 · cited 1×
“TP53 inactivation results in STAT3 hyperactivation in a TP53-null mouse model [79].”
BackgroundHIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer
de Heer, E. C., Jalving, M., & Harris, A. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137552 · Cited by 372
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369 · cited 1×
“Signal transduction pathways are altered in pancreatic cancers and affect various properties of the tumor microenvironment [68].”
BackgroundJiang, S., Zhang, L., Zhang, H., Hu, S., Lu, M., Liang, S., Li, B., Li, Y., Li, D., Wang, E., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.45 · Cited by 356 · cited 3×
“Some of these genes include hexokinase 1 (HK1), hexokinase 2 (HK2), glucose-6-phosphate isomerase (GPI), and lactate dehydrogenase a (LDHA) [131,132].”
BackgroundBinenbaum, Y., Fridman, E., Yaari, Z., Milman, N., Schroeder, A., Ben David, G., Shlomi, T., & Gil, Z. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0124 · Cited by 337 · cited 1×
“Treatment with a miR-365 antagonist (antagomiRs) resulted in sensitivity to gemcitabine [54].”
BackgroundCell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 336
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334 · cited 1×
“In contrast, TP53 can induce both p21Cip-1 and miR-34, and this results in suppression of certain markers associated with stemness such as the transcription factors Oct-4, SRY (sex determining region Y)-box 2 (Sox-2) and Nanog homeobox (Nanog) [104,105].”
BackgroundClinical Overview of MDM2/X-Targeted Therapies
Burgess, A., Chia, K. M., Haupt, S., Thomas, D., Haupt, Y., & Lim, E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00007 · Cited by 315 · cited 1×
“Various MDM2/MDM4 inhibitors and their presence in clinical trials have been summarized [182].”
BackgroundKent, O. A., Chivukula, R. R., Mullendore, M., Wentzel, E. A., Feldmann, G., Lee, K. H., Liu, S., Leach, S. D., Maitra, A., & Mendell, J. T. (2010) · Genes & Development · doi:10.1101/gad.1950610 · Cited by 311 · cited 1×
“Oncogenic KRas, which is present in virtually all PDACs, represses miR-143/miR-155 expression and this could contribute to the PDAC tumor microenvironment [135].”
Backgroundp53 and MicroRNA-34 Are Suppressors of Canonical Wnt Signaling
Kim, N. H., Kim, H. S., Kim, N.-G., Lee, I., Choi, H.-S., Li, X.-Y., Kang, S. E., Cha, S. Y., Ryu, J. K., Na, J. M., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001744 · Cited by 308 · cited 1×
“TP53 can modulate Wnt signaling via miR-34 [91].”
BackgroundYin, Z., Ma, T., Huang, B., Lin, L., Zhou, Y., Yan, J., Zou, Y., & Chen, S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1313-x · Cited by 304 · cited 1×
“This resulted in activation of the TGF-β signaling pathway, which led PDAC migration, invasion and tumor formation in mouse models [52].”
BackgroundSchwitalla, S., Ziegler, P. K., Horst, D., Becker, V., Kerle, I., Begus-Nahrmann, Y., Lechel, A., Rudolph, K. L., Langer, R., Slotta-Huspenina, J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.014 · Cited by 296 · cited 1×
“In TP53-null mice, hyperactivation of NF-κB signaling occurs in T cells, macrophages and intestinal epithelium [76].”
BackgroundNUPR1 is a critical repressor of ferroptosis
Liu, J., Song, X., Kuang, F., Zhang, Q., Xie, Y., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Communications · doi:10.1038/s41467-021-20904-2 · Cited by 290 · cited 1×
“Recently, NUPR1 has been determined to play critical roles in ferroptosis in PDCA [162].”
BackgroundKRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Chen, N., Fang, W., Lin, Z., Peng, P., Wang, J., Zhan, J., Hong, S., Huang, J., Liu, L., Sheng, J., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2005-z · Cited by 288 · cited 6×
“IFNα, IFNβ and IFNγ can increase the expression of PD-L1 in pancreatic cancer [81].”
BackgroundInfluentialMcCubrey, J. A., Lertpiriyapong, K., Steelman, L. S., Abrams, S. L., Yang, L. V., Murata, R. M., Rosalen, P. L., Scalisi, A., Neri, L. M., Cocco, L., et al. (2017) · Aging · doi:10.18632/aging.101250 · Cited by 285 · cited 1×
“It is an isoquinoline quaternary alkaloid (a 5,6-dihydrodibenzo[a,g]quinolizinium) derivative [198].”
BackgroundSelf-citationA Systematic Review of miR-29 in Cancer
Kwon, J. J., Factora, T. D., Dey, S., & Kota, J. (2019) · Molecular Therapy Oncolytics · doi:10.1016/j.omto.2018.12.011 · Cited by 263 · cited 1×
“TP53 can induce the expression of miR-29 in certain cancers [34,39].”
BackgroundLi, H., Wang, X., Wen, C., Huo, Z., Wang, W., Zhan, Q., Cheng, D., Chen, H., Deng, X., Peng, C., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0738-0 · Cited by 260 · cited 1×
“This contributes to hypoxia-induced EMT in PDAC [98].”
BackgroundThe Regulation of Ferroptosis by Tumor Suppressor p53 and its Pathway
Liu, J., Zhang, C., Wang, J., Hu, W., & Feng, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218387 · Cited by 249 · cited 1×
“TP53 can induce or suppress ferroptosis depending on the cell context [140].”
BackgroundThe Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment
Li, N., Grivennikov, S. I., & Karin, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.018 · Cited by 245 · cited 2×
“This is important in inflammation and tumorigenesis [78].”
BackgroundChaika, N. V., Gebregiworgis, T., Lewallen, M. E., Purohit, V., Radhakrishnan, P., Liu, X., Zhang, B., Mehla, K., Brown, R. B., Caffrey, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203339109 · Cited by 227 · cited 1×
“HIF-1α also increases GLUT-1 levels [128] as well the expression of glycolysis-related genes [129].”
BackgroundControl of metabolism by p53 – Cancer and beyond
Labuschagne, C. F., Zani, F., & Vousden, K. H. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.001 · Cited by 219
Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression
Liu, J., Zhang, C., Zhao, Y., Yue, X., Wu, H., Huang, S., Chen, J., Tomsky, K., Xie, H., Khella, C. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01947-w · Cited by 213 · cited 1×
“Parkin ubiquitinates HIF-1α which results in its proteasomal degradation [119].”
BackgroundJamieson, N. B., Morran, D. C., Morton, J. P., Ali, A., Dickson, E. J., Carter, C. R., Sansom, O. J., Evans, T. R. J., McKay, C. J., & Oien, K. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0679 · Cited by 207 · cited 1×
“As TP53 is frequently mutated in PDAC and low levels of miR-34a are associated with a poor prognosis [133].”
BackgroundHypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Daniel, S. K., Sullivan, K. M., Labadie, K. P., & Pillarisetty, V. G. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0226-9 · Cited by 207
LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9
Fu, Z., Chen, C., Zhou, Q., Wang, Y., Zhao, Y., Zhao, X., Li, W., Zheng, S., Ye, H., Wang, L., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.019 · Cited by 204 · cited 3×
“WDR5 is a component of the histone H3K4 methyltransferase complex and modulates the expression of HOXA9 [95].”
BackgroundInfluentialWartenberg, M., Cibin, S., Zlobec, I., Vassella, E., Eppenberger-Castori, S., Terracciano, L., Eichmann, M. D., Worni, M., Gloor, B., Perren, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3401 · Cited by 197 · cited 1×
“This also increased the levels of forkhead box P3 positive (Fox3P) Tregs and was associated with a lower level of survival in PDAC patients [16].”
BackgroundShi, M., Cui, J., Du, J., Wei, D., Jia, Z., Zhang, J., Zhu, Z., Gao, Y., & Xie, K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0186 · Cited by 194 · cited 1×
“HIF-1α also increases GLUT-1 levels [128] as well the expression of glycolysis-related genes [129].”
BackgroundAPR-246 induces early cell death by ferroptosis in acute myeloid leukemia
Birsen, R., Larrue, C., Decroocq, J., Johnson, N., Guiraud, N., Gotanegre, M., Cantero-Aguilar, L., Grignano, E., Huynh, T., Fontenay, M., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.259531 · Cited by 182 · cited 1×
“The small molecule mutant TP53 reactivator APR-246 can also induce ferroptosis in acute myeloid leukemia cells which have mutant TP53 [142].”
BackgroundAutophagy as a therapeutic target in pancreatic cancer
Piffoux, M., Eriau, E., & Cassier, P. A. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01039-5 · Cited by 181 · cited 1×
“Autophagy plays important roles in pancreatic cancer and the PDAC microenvironment [143].”
Backgroundp53 and NF‐κB: different strategies for responding to stress lead to a functional antagonism
Ak, P., & Levine, A. J. (2010) · The FASEB Journal · doi:10.1096/fj.10-160549 · Cited by 178
Wnt/β-Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance
Ram Makena, M., Gatla, H., Verlekar, D., Sukhavasi, S., K. Pandey, M., & C. Pramanik, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174242 · Cited by 178 · cited 1×
“The Wnt/β-catenin signaling pathway is important in the PDAC microenvironment as it stimulates EMT and stem-like phenotype, tumor progression and drug resistance [89,90].”
BackgroundLu, C., Talukder, A., Savage, N. M., Singh, N., & Liu, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1291106 · Cited by 176
Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
Li, Y., & Prives, C. (2007) · Oncogene · doi:10.1038/sj.onc.1210311 · Cited by 174
Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells
Zdanov, S., Mandapathil, M., Abu Eid, R., Adamson-Fadeyi, S., Wilson, W., Qian, J., Carnie, A., Tarasova, N., Mkrtichyan, M., Berzofsky, J. A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0241 · Cited by 159 · cited 1×
“This can result in the differentiation of CD4+CD25− cells into T regulatory (Treg) cells [7] and recruitment in colorectal cancer (CRC), PDAC and other cancers [8].”
BackgroundStromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment
Garcia Garcia, C. J., Huang, Y., Fuentes, N. R., Turner, M. C., Monberg, M. E., Lin, D., Nguyen, N. D., Fujimoto, T. N., Zhao, J., Lee, J. J., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.02.024 · Cited by 158 · cited 2×
“Treatment of mice with PDAC tumors with PT2399 inhibited macrophage hemotaxis and M2 polarization and improved responses to immunotherapy as well as mouse survival [31].”
BackgroundThe Mevalonate Pathway, a Metabolic Target in Cancer Therapy
Guerra, B., Recio, C., Aranda-Tavío, H., Guerra-Rodríguez, M., García-Castellano, J. M., & Fernández-Pérez, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626971 · Cited by 157 · cited 1×
“When the MVA pathway is at elevated levels, stabilization of the GOF mut-TP53 protein occurs which promotes protein prenylation and enhances cancer progression [138].”
BackgroundKim, M. P., Li, X., Deng, J., Zhang, Y., Dai, B., Allton, K. L., Hughes, T. G., Siangco, C., Augustine, J. J., Kang, Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1228 · Cited by 153 · cited 6×
“NF-κB and TP53 may compete for the transcription coactivator p300 and the cyclic AMP response element binding protein1 (CREB1) [73,74].”
BackgroundInfluentialGarg, B., Giri, B., Modi, S., Sethi, V., Castro, I., Umland, O., Ban, Y., Lavania, S., Dawra, R., Banerjee, S., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.05.051 · Cited by 152
Hypoxia-induced Nucleophosmin Protects Cell Death through Inhibition of p53
Li, J., Zhang, X., Sejas, D. P., Bagby, G. C., & Pang, Q. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400297200 · Cited by 149 · cited 1×
“Hypoxia inhibits TP53 activity by blocking the phosphorylation of the regulatory S15 and S293 on the TP53 protein [115,116].”
BackgroundDoi, T., Ishikawa, T., Okayama, T., Oka, K., Mizushima, K., Yasuda, T., Sakamoto, N., Katada, K., Kamada, K., Uchiyama, K., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5399 · Cited by 149 · cited 1×
“IFNα, IFNβ and IFNγ can increase the expression of PD-L1 in pancreatic cancer [81].”
BackgroundHashimoto, S., Furukawa, S., Hashimoto, A., Tsutaho, A., Fukao, A., Sakamura, Y., Parajuli, G., Onodera, Y., Otsuka, Y., Handa, H., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901765116 · Cited by 149 · cited 6×
“IFNα, IFNβ and IFNγ can increase the expression of PD-L1 in pancreatic cancer [81].”
BackgroundInfluentialCritical role of NF-κB in pancreatic cancer
Prabhu, L., Mundade, R., Korc, M., Loehrer, P. J., & Lu, T. (2014) · Oncotarget · doi:10.18632/oncotarget.2624 · Cited by 148 · cited 6×
“Cells 2022, 11, 2155. https://doi.org/10.3390/cells11142155 https://www.mdpi.com/journal/cells KRAS is mutated in >95% of PDACs.”
BackgroundInfluentialCancer-Associated Fibroblasts: Understanding Their Heterogeneity
Louault, K., Li, R.-R., & DeClerck, Y. A. (2020) · Cancers · doi:10.3390/cancers12113108 · Cited by 148
Glucose Metabolism in Pancreatic Cancer
Liang, Y., Raj, P. S., Yao, W., & Ying, H. (2019) · Cancers · doi:10.3390/cancers11101460 · Cited by 145 · cited 1×
“Metabolic reprogramming occurs in the PDAC microenvironment which is crucial for PDAC tumorigenesis [109].”
BackgroundTiwari, A., Tashiro, K., Dixit, A., Soni, A., Vogel, K., Hall, B., Shafqat, I., Slaughter, J., Param, N., Le, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.07.046 · Cited by 142 · cited 1×
“Loss of HIF-1α led to increased levels of protein phosphatase 1 regulatory inhibitor subunit 1B (PPRIR1B) and resulted in degradation of TP53, invasion, and metastasis [97].”
BackgroundTumor Suppressor p53 Inhibits Autoimmune Inflammation and Macrophage Function
Zheng, S.-J., Lamhamedi-Cherradi, S.-E., Wang, P., Xu, L., & Chen, Y. H. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1423 · Cited by 141 · cited 4×
“Restoration of WT-TP53 activity suppressed inflammation and autoimmunity [20].”
BackgroundInfluentialAmelio, I., Mancini, M., Petrova, V., Cairns, R. A., Vikhreva, P., Nicolai, S., Marini, A., Antonov, A. A., Le Quesne, J., Baena Acevedo, J. D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808314115 · Cited by 139 · cited 1×
“Two prominent ECM components that are affected by this interaction are type VIIa1 collagen and laminin-γ2, which promote tumor progression [100].”
BackgroundPrognostic significance of HIF-1 alpha overexpression in human pancreatic cancer.
(2003) · PubMed · Cited by 138
Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets
Whittle, M. C., & Hingorani, S. R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.044 · Cited by 137 · cited 1×
“CAFs are the main producers of stoma [29].”
BackgroundHypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT
Leszczynska, K. B., Foskolou, I. P., Abraham, A. G., Anbalagan, S., Tellier, C., Haider, S., Span, P. N., O’Neill, E. E., Buffa, F. M., & Hammond, E. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80402 · Cited by 133 · cited 1×
“Hypoxia inhibits TP53 activity by blocking the phosphorylation of the regulatory S15 and S293 on the TP53 protein [115,116].”
BackgroundCui, Y., & Guo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111942 · Cited by 133 · cited 1×
“Mut-TP53 can alter immunosuppressive properties of the PDAC microenvironment which accelerates tumor progression and metastasis [10].”
BackgroundThe miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer
Xiao, X., Huang, X., Ye, F., Chen, B., Song, C., Wen, J., Zhang, Z., Zheng, G., Tang, H., & Xie, X. (2016) · Scientific Reports · doi:10.1038/srep21735 · Cited by 132 · cited 1×
“Some of these genes include hexokinase 1 (HK1), hexokinase 2 (HK2), glucose-6-phosphate isomerase (GPI), and lactate dehydrogenase a (LDHA) [131,132].”
BackgroundSynthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer
Genovese, G., Carugo, A., Tepper, J., Robinson, F. S., Li, L., Svelto, M., Nezi, L., Corti, D., Minelli, R., Pettazzoni, P., et al. (2017) · Nature · doi:10.1038/nature21064 · Cited by 131 · cited 1×
“Depletion of Smarcb1 activated the Myc network which resulted in an anabolic shift which resulted in increased protein metabolism and activation of ER stress and unfolded protein response [176].”
BackgroundHamidi, T., Algül, H., Cano, C. E., Sandi, M. J., Molejon, M. I., Riemann, M., Calvo, E. L., Lomberk, G., Dagorn, J.-C., Weih, F., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60144 · Cited by 130 · cited 2×
“Genetic studies indicated that in the absence of NUPR1 in a mouse model, mut-KRAS (G12D) did not result in the development of PanIns, which is a precursor of the high lethal PDAC [155,156].”
BackgroundYang, Y., Ishak Gabra, M. B., Hanse, E. A., Lowman, X. H., Tran, T. Q., Li, H., Milman, N., Liu, J., Reid, M. A., Locasale, J. W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08759-0 · Cited by 129 · cited 1×
“miR-135 and mut-TP53 confer a loop that allows the PDAC cancer to survive in the nutrient poor PDAC microenvironment and permits the PDAC cells to survive under metabolic stresses [53].”
BackgroundZhang, Q., Lou, Y., Zhang, J., Fu, Q., Wei, T., Sun, X., Chen, Q., Yang, J., Bai, X., & Liang, T. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0689-5 · Cited by 128 · cited 1×
“In the hypoxic PDAC microenvironment, HIF-2α induces Wnt signaling via β-catenin and SMAD4 and increases tumor progression [93].”
BackgroundEmma, M. R., Iovanna, J. L., Bachvarov, D., Puleio, R., Loria, G. R., Augello, G., Candido, S., Libra, M., Gulino, A., Cancila, V, et al. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.175 · Cited by 126 · cited 7×
“Normally, sorafenib treatment of HCC cells results in activation of autophagic flux.”
BackgroundSelf-citationp53 regulates glucose metabolism by miR-34a
Kim, H.-R., Roe, J., Lee, J., Cho, E., & Youn, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.043 · Cited by 124 · cited 1×
“Some of these genes include hexokinase 1 (HK1), hexokinase 2 (HK2), glucose-6-phosphate isomerase (GPI), and lactate dehydrogenase a (LDHA) [131,132].”
BackgroundMetformin and berberine, two versatile drugs in treatment of common metabolic diseases
Wang, H., Zhu, C., Ying, Y., Luo, L., Huang, D., & Luo, Z. (2018) · Oncotarget · doi:10.18632/oncotarget.20807 · Cited by 122 · cited 1×
“In addition, a low dose of metformin could interact with chemically-modified berberines (NAX compounds) and lower the concentrations of berberine (BBR) and certain NAX compounds required to reach the IC50, indicating that metformin could increase drug sensitivity in terms of proliferation [196].”
BackgroundHuang, C., Li, Z., Li, N., Li, Y., Chang, A., Zhao, T., Wang, X., Wang, H., Gao, S., Yang, S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.09.039 · Cited by 121
Maddalena, M., Mallel, G., Nataraj, N. B., Shreberk-Shaked, M., Hassin, O., Mukherjee, S., Arandkar, S., Rotkopf, R., Kapsack, A., Lambiase, G., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025631118 · Cited by 114 · cited 2×
“This tumor microenvironment suppresses the ability of the immune system to eliminate the PDAC and results in a poor PDAC prognosis [64].”
BackgroundDenley, S. M., Jamieson, N. B., McCall, P., Oien, K. A., Morton, J. P., Carter, C. R., Edwards, J., & McKay, C. J. (2013) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-013-2168-7 · Cited by 113 · cited 2×
“l t e ressi f t e J ST at a is ass ciate it a r r sis i [77].”
BackgroundMdm2 and MdmX partner to regulate p53
Wang, X., & Jiang, X. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.02.049 · Cited by 111 · cited 1×
“When MDM2 is heterodimerized with MDM4, polyubiquitination of TP53 occurs [181].”
Backgroundp53 Status in Stromal Fibroblasts Modulates Tumor Growth in an SDF1-Dependent Manner
Addadi, Y., Moskovits, N., Granot, D., Lozano, G., Carmi, Y., Apte, R. N., Neeman, M., & Oren, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1146 · Cited by 108
Falcomatà, C., Bärthel, S., Widholz, S. A., Schneeweis, C., Montero, J. J., Toska, A., Mir, J., Kaltenbacher, T., Heetmeyer, J., Swietlik, J. J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-021-00326-1 · Cited by 108
Zhang, L., & Hill, R. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3038 · Cited by 107 · cited 1×
“Hypoxic conditions will induce the expression of two negative regulators of TP53, namely MDM2 and MDM4 in some cell types [113,114].”
BackgroundDesmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression
Duan, W., Chen, K., Jiang, Z., Chen, X., Sun, L., Li, J., Lei, J., Xu, Q., Ma, J., Li, X., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.019 · Cited by 106
MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer
Khan, S., Ebeling, M. C., Zaman, M. S., Sikander, M., Yallapu, M. M., Chauhan, N., Yacoubian, A. M., Behrman, S. W., Zafar, N., Kumar, D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2281 · Cited by 105 · cited 1×
“miR-145 functions as a tumor-suppressor in pancreatic cancer and inhibits the expression of the mucin 13 (MUC13) gene [44].”
BackgroundLigand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis
Santofimia-Castaño, P., Xia, Y., Lan, W., Zhou, Z., Huang, C., Peng, L., Soubeyran, P., Velázquez-Campoy, A., Abián, O., Rizzuti, B., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127223 · Cited by 104 · cited 1×
“ZZW-115 is a NUPR1 inhibitor which induces necroptosis [163,164].”
BackgroundAntithetical NFATc1–Sox2 and p53–miR200 signaling networks govern pancreatic cancer cell plasticity
Singh, S. K., Chen, N., Heßmann, E., Siveke, J. T., Lahmann, M., Singh, G., Völker, N., Vogt, S., Esposito, I., Schmidt, A., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201489574 · Cited by 102 · cited 1×
“The TP53/miR-200 axis is important in PDAC [59].”
BackgroundRaj, N., & Bam, R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00159 · Cited by 100
Hypoxia-mediated cancer stem cell resistance and targeted therapy
Sun, X., Lv, X., Yan, Y., Zhao, Y., Ma, R., He, M., & Wei, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110623 · Cited by 99 · cited 1×
“Octamer-binding transcription factor 4 (Oct-4) is a transcription factor that has been observed to be induced in cancer cells under hypoxic conditions [102,103].”
BackgroundThe Interplay Between Tumor Suppressor p53 and Hypoxia Signaling Pathways in Cancer
Zhang, C., Liu, J., Wang, J., Zhang, T., Xu, D., Hu, W., & Feng, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.648808 · Cited by 95
Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
Jiang, B., Zhou, L., Lu, J., Wang, Y., Liu, C., You, L., & Guo, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.576399 · Cited by 93
Zheng, S., Hu, C., Lin, H., Li, G., Xia, R., Zhang, X., Su, D., Li, Z., Zhou, Q., & Chen, R. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02237-6 · Cited by 90 · cited 2×
“The effects of the circCUL2 RNA were examined in cells with an inflammatory CAF phenotype in the PDAC microenvironment [36].”
BackgroundClark, D., Mitra, A., Fillmore, R., Jiang, W., Samant, R., Fodstad, O., & Shevde, L. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908785133196 · Cited by 89 · cited 1×
“The NUPR1 protein can interact with TP53 in immortalized breast epithelial cells [154].”
BackgroundKaymak, I., Maier, C. R., Schmitz, W., Campbell, A. D., Dankworth, B., Ade, C. P., Walz, S., Paauwe, M., Kalogirou, C., Marouf, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-0650 · Cited by 89 · cited 1×
“This is required in metabolically comprised environment such as colon spheroid cultures and colon tumor organoids for respiration and pyrimidine synthesis [139].”
BackgroundLi, J., Lama, R., Galster, S. L., Inigo, J. R., Wu, J., Chandra, D., Chemler, S. R., & Wang, X. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0728 · Cited by 87 · cited 2×
“The small molecule inhibitor MMRi62 was initially characterized as a molecule which disrupted the activity of MDM2 and MDM4 and could induce apoptosis in a TP53-independent fashion in PDAC both in vitro and in vivo [141].”
BackgroundLiu, Y., Deguchi, Y., Wei, D., Liu, F., Moussalli, M. J., Deguchi, E., Li, D., Wang, H., Valentin, L. A., Colby, J. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30392-7 · Cited by 84 · cited 2×
“Activation of PPARδ by either a high fat diet or a highlyselective synthetic PPARδ ligand accelerated PDAC development in KRASG12D mutant mice [197].”
BackgroundTumor Suppressor p53 Inhibits Systemic Autoimmune Diseases by Inducing Regulatory T Cells
Kawashima, H., Takatori, H., Suzuki, K., Iwata, A., Yokota, M., Suto, A., Minamino, T., Hirose, K., & Nakajima, H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300509 · Cited by 83 · cited 1×
“Loss of WT-TP53 activity altered Treg differentiation and led to inflammation [22,23].”
BackgroundOxidative stress-induced p53 activity is enhanced by a redox-sensitive TP53INP1 SUMOylation
Peuget, S., Bonacci, T., Soubeyran, P., Iovanna, J., & Dusetti, N. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.28 · Cited by 83
Murakami, S., Nemazanyy, I., White, S. M., Chen, H., Nguyen, C. D. K., Graham, G. T., Saur, D., Pende, M., & Yi, C. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.07.022 · Cited by 83 · cited 1×
“YAP has been shown to promote keys events in KRas-mediated pancreatic cancer tumorigenesis, namely: growth, drug resistance, metabolic reprogramming, differentiation, EMT and metastasis [83,84].”
BackgroundHuang, X., He, C., Hua, X., Kan, A., Mao, Y., Sun, S., Duan, F., Wang, J., Huang, P., & Li, S. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.41 · Cited by 83
Carvalho, T. M. A., Molfetta, D. D., Greco, M. R., Koltai, T., Alfarouk, K. O., Reshkin, S. J., & Cardone, R. A. (2021) · Cancers · doi:10.3390/cancers13236135 · Cited by 82 · cited 4×
“Fibrosis is due to the deposition of the ECM and collagen fibers.”
BackgroundInfluentialLiu, Y., Tang, T., Yang, X., Qin, P., Wang, P., Zhang, H., Bai, M., Wu, R., & Li, F. (2021) · Oncogene · doi:10.1038/s41388-021-01762-0 · Cited by 80 · cited 1×
“LINC01133 was detected in exosomes of advanced PDAC patients and correlated with a poor overall survival [94].”
BackgroundExploiting inflammation for therapeutic gain in pancreatic cancer
Steele, C. W., Jamieson, N. B., Evans, T. R. J., McKay, C. J., Sansom, O. J., Morton, J. P., & Carter, C. R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.24 · Cited by 79 · cited 1×
“KRAS mutations can affect the infiltration of T cells and myeloid-derived suppressive cells (MDSCs) during early stages of pancreatic intraepithelial neoplasia (PanIN) [3].”
BackgroundPark, J., Lim, M., Cho, M., Ryu, J., Moon, Y., Jhun, J., Byun, J. K., Kim, E., Hwang, S., Ju, J. H., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37841 · Cited by 77
Palamaris, K., Felekouras, E. S., & Sakellariou, S. (2021) · Cancers · doi:10.3390/cancers13215532 · Cited by 76 · cited 1×
“The Wnt/β-catenin signaling pathway is important in the PDAC microenvironment as it stimulates EMT and stem-like phenotype, tumor progression and drug resistance [89,90].”
BackgroundActivated p53 induces NF-κB DNA binding but suppresses its transcriptional activation
Kawauchi, K., Araki, K., Tobiume, K., & Tanaka, N. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.021 · Cited by 75 · cited 7×
“NF-κB and TP53 may compete for the transcription coactivator p300 and the cyclic AMP response element binding protein1 (CREB1) [73,74].”
BackgroundInfluentialPathophysiological role of microRNA-29 in pancreatic cancer stroma
Kwon, J. J., Nabinger, S. C., Vega, Z., Sahu, S. S., Alluri, R. K., Sater, Z. A., Yu, Z., Gore, J., Nalepa, G., Saxena, R., et al. (2015) · Scientific Reports · doi:10.1038/srep11450 · Cited by 75 · cited 2×
“miR-29a has been shown to affect PSCs and alter the regulation of the PDAC microenvironment [32].”
BackgroundSi, L., Xu, L., Yin, L., Qi, Y., Han, X., Xu, Y., Zhao, Y., Liu, K., & Peng, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13718 · Cited by 75 · cited 1×
“The expression of miR-141, miR-149 and mi-429 are regulated by TP53 in some cancers such as gastrointestinal cancers including PDAC [60,61].”
BackgroundRegulatory role of p53 in experimental autoimmune encephalomyelitis
Okuda, Y., Okuda, M., & Bernard, C. C. A. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00428-9 · Cited by 74 · cited 1×
“Inhibition of normal TP53 function led to T cell differentiation into T helper Th17 cells [21].”
BackgroundMicro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer
Zhang, L., Yao, J., Li, W., & Zhang, C. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14934840662335 · Cited by 72 · cited 1×
“in CAFs in the tumor transplant studies resulted in inhibition of PDAC desmoplasia and led to sensitization to gemcitabine [47].”
BackgroundFerrari, E., & Gandellini, P. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03192-4 · Cited by 72 · cited 1×
“TP53 can regulate the expression of miR-205 [57].”
BackgroundStalnecker, C. A., Grover, K. R., Edwards, A. C., Coleman, M. F., Yang, R., DeLiberty, J. M., Papke, B., Goodwin, C. M., Pierobon, M., Petricoin, E. F., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1443 · Cited by 69 · cited 1×
“Further studies by this same group indicated that suppression of both insulin-like growth factor-1 receptor (IGF-1R) and ERK signaling synergized with autophagy inhibitors to inhibit the growth of PDAC [179].”
BackgroundJiang, Z., Zhou, C., Cheng, L., Yan, B., Chen, K., Chen, X., Zong, L., Lei, J., Duan, W., Xu, Q., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0740-4 · Cited by 68 · cited 1×
“This results in the expression of multiple cytokines and chemokines which alter the differentiation and presence of MDSCs in the PDAC microenvironment [85,86].”
BackgroundNUPR1: A Critical Regulator of the Antioxidant System
Huang, C., Santofimia-Castaño, P., & Iovanna, J. (2021) · Cancers · doi:10.3390/cancers13153670 · Cited by 66
Viotti, J., Duplan, E., Caillava, C., Condat, J., Goiran, T., Giordano, C., Marie, Y., Idbaih, A., Delattre, J.-Y., Honnorat, J., et al. (2014) · Oncogene · doi:10.1038/onc.2013.124 · Cited by 65 · cited 1×
“TP53 can induce PARKIN gene expression which affects glucose metabolism and inhibits breast cancer progression [117,118].”
BackgroundChen, B., Longtine, M. S., Sadovsky, Y., & Nelson, D. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00154.2010 · Cited by 64 · cited 1×
“Hypoxic conditions will induce the expression of two negative regulators of TP53, namely MDM2 and MDM4 in some cell types [113,114].”
BackgroundNew landscapes and horizons in hepatocellular carcinoma therapy
Cervello, M., Emma, M. R., Augello, G., Cusimano, A., Giannitrapani, L., Soresi, M., Akula, S. M., Abrams, S. L., Steelman, L. S., Gulino, A., et al. (2020) · Aging · doi:10.18632/aging.102777 · Cited by 63 · cited 1×
“It is approved by the FDA to treat many diseases such as hepatocellular carcinoma [175].”
BackgroundSelf-citationSheikh, A. A., Vimalachandran, D., Thompson, C. C., Jenkins, R. E., Nedjadi, T., Shekouh, A., Campbell, F., Dodson, A. R., Prime, W., Crnogorac‐Jurcevic, T., et al. (2007) · PROTEOMICS · doi:10.1002/pmic.200700072 · Cited by 61 · cited 1×
“It can induce neutrophil chemotaxis and adhesion [18].”
BackgroundTargeting Fibrosis: The Bridge That Connects Pancreatitis and Pancreatic Cancer
Huang, C., Iovanna, J., & Santofimia‐Castaño, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094970 · Cited by 61 · cited 1×
“NUPR1 may be a critical transcription factor which is induced in response to the cellular stress and could be a therapeutic target in pancreatic cancer progression [161].”
BackgroundThe p53/microRNA connection in gastrointestinal cancer
Hermeking, H., Rokavec, M., Li, H., & Jiang, L. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s43738 · Cited by 59 · cited 1×
“miR145 is regulated by TP53 in various cancers including pancreatic cancer [43].”
BackgroundMIR506induces autophagy-related cell death in pancreatic cancer cells by targeting the STAT3 pathway
Sun, L., Hu, L., Cogdell, D. E., Lü, L., Gao, C., Tian, W., Zhang, Z., Kang, Y., Fleming, J. B., & Zhang, W. (2017) · Autophagy · doi:10.1080/15548627.2017.1280217 · Cited by 58 · cited 1×
“and LncRNAs are involved in the regulation of autophagy; these include miR-506 [145], miR-372 [146] and LncRNA PVT1 [147].”
BackgroundTargeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma
Santofimia-Castaño, P., Xia, Y., Peng, L., Velázquez-Campoy, A., Abián, O., Lan, W., Lomberk, G., Urrutia, R., Rizzuti, B., Soubeyran, P., et al. (2019) · Cells · doi:10.3390/cells8111453 · Cited by 58 · cited 2×
“ZZW-115 bound the NLS region of NUPR1 [164].”
BackgroundNUPR1 and its potential role in cancer and pathological conditions (Review)
Martin, T. A., Li, A., Sanders, A. J., Ye, L., Frewer, K. A., Hargest, R., & Jiang, W. G. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5201 · Cited by 57 · cited 1×
“The NUPR1 and TP53 proteins play critical roles in cancer [153].”
BackgroundKamat, C. D., Green, D. E., Warnke, L. A., Thorpe, J. E., Ceriello, A., & Ihnat, M. A. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.08.017 · Cited by 56 · cited 14×
“In mice lacking WT-TP53 but containing mutant KRAS, loss of autophagy did not block tumor growth but accelerated tumor onset by increasing glucose uptake and anabolic pathways which accelerated tumor growth.”
BackgroundInfluentialCancer-Associated Fibroblasts’ Functional Heterogeneity in Pancreatic Ductal Adenocarcinoma
Awaji, M. I., & Singh, R. K. (2019) · Cancers · doi:10.3390/cancers11030290 · Cited by 56 · cited 1×
“CAFs are important cells during the desmoplastic reaction in PDAC [40].”
BackgroundGrasso, D., Garcia, M. N., Hamidi, T., Cano, C. E., Calvo, E. L., Lomberk, G. A., Urrutia, R. A., & Iovanna, J. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.74 · Cited by 55 · cited 1×
“Subsequently, it was determined that NUPR1 interacted with mut-KRas in the induction of senescence-associated gene networks [157].”
BackgroundIER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation
Garcia, M. N., Grasso, D., López‐Millán, B., Hamidi, T., Loncle, C., Tomasini, R., Lomberk, G. A., Porteu, F., Urrutia, R. A., & Iovanna, J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76037 · Cited by 55 · cited 1×
“IRE3 was determined to be responsible for an activation of ERK1/ERK2 by inhibiting protein phosphatase 2A (PP2A) dephosphorylation, which resulted in proliferation and PDAC development [159].”
BackgroundSun, Q., Fan, G., Zhuo, Q., Dai, W., Zeng, Y., Ji, S., Xu, W., Liu, W., Hu, Q., Zhang, Z., et al. (2020) · Cell Proliferation · doi:10.1111/cpr.12816 · Cited by 54 · cited 1×
“The expression of these cytokines contributes to pancreatic cancer progression and metastasis [71].”
BackgroundNedjadi, T., Evans, A., Sheikh, A., Barerra, L., Al-Ghamdi, S., Oldfield, L., Greenhalf, W., Neoptolemos, J. P., & Costello, E. (2018) · BMC Cancer · doi:10.1186/s12885-018-5161-4 · Cited by 53 · cited 1×
“S100A8 is associated with the tumor microenvironment as it increases the secretion of pro-inflammatory cytokines [19].”
BackgroundLan, W., Santofimia-Castaño, P., Swayden, M., Xia, Y., Zhou, Z., Audebert, S., Camoin, L., Huang, C., Peng, L., Jiménez-Alesanco, A., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138117 · Cited by 53 · cited 3×
“ZZW-115 treatment was determined to suppress the SUMOylation of several key proteins involved in the DNA damage response (DDR).”
BackgroundInfluentialHayashi, Y., Tsujii, M., Kodama, T., Akasaka, T., Kondo, J., Hikita, H., Inoue, T., Tsujii, Y., Maekawa, A., Yoshii, S., et al. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw085 · Cited by 52 · cited 1×
“In colon cancer models, mutant TP53 can induce the expression of vascular endothelial growth factor (VEGF) which promotes angiogenesis and tumorigenesis [14].”
BackgroundStroma-derived extracellular vesicles deliver tumor-suppressive miRNAs to pancreatic cancer cells
Han, S., Gonzalo, D. H., Feely, M., Rinaldi, C., Belsare, S., Zhai, H., Kalra, K., Gerber, M. H., Forsmark, C. E., & Hughes, S. J. (2017) · Oncotarget · doi:10.18632/oncotarget.23532 · Cited by 52 · cited 1×
“In this situation, the TAS suppressed tumor growth [42].”
BackgroundMUC13 contributes to rewiring of glucose metabolism in pancreatic cancer
Kumari, S., Khan, S., Gupta, S. C., Kashyap, V. K., Yallapu, M. M., Chauhan, S. C., & Jaggi, M. (2018) · Oncogenesis · doi:10.1038/s41389-018-0031-0 · Cited by 51
Metformin influences drug sensitivity in pancreatic cancer cells
Candido, S., Abrams, S. L., Steelman, L. S., Lertpiriyapong, K., Martelli, A. M., Cocco, L., Ratti, S., Follo, M. Y., Murata, R. M., Rosalen, P. L., et al. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.02.002 · Cited by 51 · cited 2×
“Metformin treatment of three different PDAC cell lines did not inhibit proliferation significantly with concentrations up to 1000 nM [195].”
BackgroundSelf-citationLiu, J., Gao, M., NIPPER, M. J., Deng, J., Sharkey, F. E., Johnson, R. L., Crawford, H. C., Chen, Y., & Wang, P. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000418 · Cited by 51 · cited 1×
“This results in the expression of multiple cytokines and chemokines which alter the differentiation and presence of MDSCs in the PDAC microenvironment [85,86].”
BackgroundEmerging Roles of the Tumor Suppressor p53 in Metabolism
Yu, L., Wu, M. Y., Zhu, G., & Xu, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.762742 · Cited by 51 · cited 1×
“TP53 plays many diverse roles in the regulation of metabolism [108].”
BackgroundYang, J., Qiu, B., Li, X., Zhang, H., & Liu, W. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.07.016 · Cited by 49 · cited 1×
“TP53 regulates the expression of miR-21 in some cancer types such as hepatocellular carcinoma [49].”
BackgroundRole of non-coding RNAs in tumor progression and metastasis in pancreatic cancer
Sempere, L. F., Powell, K., Rana, J., Brock, A. A., & Schmittgen, T. D. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09995-x · Cited by 49 · cited 3×
“miR-21 is also important in the PDAC microenvironment [35].”
BackgroundInfluentialChen, H., Zhang, Z., Lu, Y., Song, K., Liu, X., Xia, F., & Sun, W. (2017) · Cancer Science · doi:10.1111/cas.13315 · Cited by 48 · cited 1×
“and LncRNAs are involved in the regulation of autophagy; these include miR-506 [145], miR-372 [146] and LncRNA PVT1 [147].”
BackgroundQian, W., Li, J., Chen, K., Jiang, Z., Cheng, L., Zhou, C., Yan, B., Cao, J., Ma, Q., & Duan, W. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.046 · Cited by 48 · cited 1×
“Combined metformin and gemcitabine treatment reduced Shh expression and altered the recruitment of tumor supportive PSCs, which reduced angiogenesis [193].”
BackgroundWang, C., Li, X., Zhang, L., Chen, Y., Dong, R., Zhang, J., Zhao, J., Guo, X., Yang, G., Yan, L., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107822 · Cited by 48 · cited 1×
“Thus, miR-194-5p may serve as a therapeutic target in PDAC by altering the tumor microenvironment [50].”
BackgroundmiR-128 Regulates Tumor Cell CD47 Expression and Promotes Anti-tumor Immunity in Pancreatic Cancer
Xi, Q., Chen, Y., Yang, G.-Z., Zhang, J.-Y., Zhang, L.-J., Guo, X.-D., Zhao, J.-Y., Xue, Z.-Y., Li, Y., & Zhang, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00890 · Cited by 47
MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma
Woodfield, S. E., Shi, Y. P., Patel, R. H., Chen, Z., Shah, A. P., Srivastava, R. K., Whitlock, R. S., Ibarra, A. M., Larson, S. R., Sarabia, S. F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82542-4 · Cited by 47 · cited 1×
“In some cells, they are expressed at different levels [180].”
BackgroundNovel mechanism of miRNA‐365‐regulated trophoblast apoptosis in recurrent miscarriage
Zhao, W., Shen, W., Cao, X., Ding, W.-Y., Yan, L., Gao, L.-J., Li, X.-L., & Zhong, T.-Y. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13163 · Cited by 45 · cited 22×
“Regulatory loops between TP53 and miR-29 exist, as TP53 can activate miR-29 expression and miR-29 can negatively regulate MDM2 expression, resulting in increased stability of TP53 [34].”
BackgroundInfluentialLi, S.-M. H., Liu, S., Chang, Y., Ho, C., & Huang, S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0478-5 · Cited by 41 · cited 1×
“The anti-type 2 diabetes drug metformin will induce AMP-activated protein kinase (AMPK), which has effects on TP53 activity in some cells [188].”
BackgroundLan, W., Santofimia‐Castaño, P., Xia, Y., Zhou, Z., Huang, C., Fraunhoffer, N. A., Barea, D., Cervello, M., Giannitrapani, L., Montalto, G., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.04.024 · Cited by 41 · cited 2×
“The effects of knock down (KD) of NUPR1 were examined in HCC cell lines [168,170,171].”
BackgroundSelf-citationCano, C. E., Hamidi, T., Garcia, M. N., Grasso, D., Loncle, C., Garcia, S., Calvo, E., Lomberk, G., Dusetti, N., Bartholin, L., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305221 · Cited by 40 · cited 1×
“The PDAC tumors which developed in the NUPR1 knock-out mice expressed higher levels of various markers associated with stemness such as aldehyde dehydrogenase 1 (ALDH1), Sox2 and Oct-4 than in mice containing WT-NUPR1 [160].”
BackgroundAkula, S. M., Candido, S., Libra, M., Abrams, S. L., Steelman, L. S., Lertpiriyapong, K., Ramazzotti, G., Ratti, S., Follo, M. Y., Martelli, A. M., et al. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.04.003 · Cited by 40 · cited 1×
“The effects of BBRs and NAX compounds on PDAC have been recently described [199,200].”
BackgroundSelf-citationParmakhtiar, B., Burger, R. A., Kim, J.-H., & Fruehauf, J. P. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1109 · Cited by 39 · cited 1×
“Topotecan treatment decreased HIF-1α levels in ovarian cancer patients which have GOF mut-TP53 [130].”
BackgroundPivotal Role of the Chromatin Protein Nupr1 in Kras-Induced Senescence and Transformation
Grasso, D., Bintz, J., Lomberk, G. A., Molejon, M. I., Loncle, C., Garcia, M. N., López‐Millán, B., Urrutia, R. A., & Iovanna, J. (2015) · Scientific Reports · doi:10.1038/srep17549 · Cited by 37 · cited 1×
“The DNA methylation inhibitor 5-aza-2’-deoxycytydine could reverse mut-KRas-induced PanIN progression by inducing senescence [158].”
BackgroundAbrams, S. L., Lertpiriyapong, K., Yang, L. V., Martelli, A. M., Cocco, L., Ratti, S., Falasca, M., Murata, R. M., Rosalen, P. L., Lombardi, P., et al. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.06.002 · Cited by 36 · cited 1×
“Introduction of a WT-TP53 gene into PDAC cells which have either GOF mut-TP53 or were TP53-null will increase their sensitivity to many chemotherapeutic drugs, signal transduction inhibitors and natural products [184,185].”
BackgroundSelf-citationLiu, Z., Chen, Y., Gao, H., Xu, W., Zhang, C., Lai, J., Liu, X., Sun, Y., & Huang, H. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s279002 · Cited by 36 · cited 1×
“A suboptimal concentration of nutlin-3a or BBR can increase the sensitivity to many of the chemotherapeutic drugs, targeted therapeutics and nutraceuticals in many cancer types [186,187].”
Backgroundp53 balances between tissue hierarchy and anarchy
Koifman, G., Aloni-Grinstein, R., & Rotter, V. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz022 · Cited by 34
Gralewska, P., Gajek, A., Marczak, A., & Rogalska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910557 · Cited by 34
miR‑212 regulated by HIF‑1α promotes the progression of pancreatic cancer
Yue, H., Liu, L., & Song, Z. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7213 · Cited by 32 · cited 1×
“Knock-down of miR-212 expression suppressed PDAC cell growth in in vitro studies [96].”
BackgroundThe Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment
Sun, H., Zhang, B., & Li, H. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820920969 · Cited by 31 · cited 1×
“The effects of the mutations and/or changes in gene expression on the PDAC microenvironment have been recently reviewed [1].”
BackgroundThe roaring 2020s: a new decade of systemic therapy for renal cell carcinoma
Srivastava, A., Doppalapudi, S. K., Patel, H. V., Srinivasan, R., & Singer, E. A. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000831 · Cited by 31 · cited 1×
“Belzutifan is an HIF-2α and HIF-1α inhibitor that is approved for the treatment of renal cell carcinoma [30].”
BackgroundConradt, L., Henrich, A., Wirth, M., Reichert, M., Lesina, M., Algül, H., Schmid, R. M., Krämer, O. H., Saur, D., & Schneider, G. (2013) · International Journal of Cancer · doi:10.1002/ijc.27916 · Cited by 30 · cited 1×
“, PXN822) will synergize with topoisomerase inhibitors (etoposide) to induce cell death in PDAC cells in a TP53-independent fashion [183].”
BackgroundThe MDM2 inhibitor Nutlin-3 modulates dendritic cell–induced T cell proliferation
Gasparini, C., Tommasini, A., & Zauli, G. (2012) · Human Immunology · doi:10.1016/j.humimm.2012.01.018 · Cited by 30 · cited 1×
“TP53 can increase the immune response in the PDAC microenvironment by augmenting the levels of T cells, which enhances the effects of dendritic cells (DC) [11].”
BackgroundLong, L., Zhan, J., Wang, H., Li, S., Chen, Y., & Liu, Y. (2016) · Pathobiology · doi:10.1159/000447302 · Cited by 30 · cited 1×
“The expression of miR-141, miR-149 and mi-429 are regulated by TP53 in some cancers such as gastrointestinal cancers including PDAC [60,61].”
BackgroundGao, Q., Lei, F., Zeng, Q., Gao, Z., Niu, P., Junnan, Ning, Li, J., & Zhang, J. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.40787 · Cited by 30 · cited 1×
“miR-2277-3p targets NUPR1L, and when NUPR1L is suppressed, proliferation, migration, and invasion of SW620 CRC cells occurred [167].”
BackgroundHan, S., Gonzalo, D. H., Feely, M., Delitto, D., Behrns, K. E., Beveridge, M. J., Zhang, D., Thomas, R. M., Trevino, J. G., Schmittgen, T. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10722 · Cited by 29 · cited 2×
“When miR-200b, miR200c and miR-205 were over expressed in TAS cells, increased granulocyte macrophage colony stimulating factor (GM-CSF) and interferon gamma-induced protein 10 (IP10) were secreted at higher levels and migration was inhibited [56].”
BackgroundHafezi, S., Saber-Ayad, M. M., & Abdel‐Rahman, W. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910219 · Cited by 28 · cited 1×
“In addition, KRAS mutations induce growth factors such as interleukin-6 (IL-6) and IL-10, transforming growth factor-β (TGF-β) and sonic hedgehog (Shh) [9].”
BackgroundLópez‐Millán, B., Garcia, M. N., Grasso, D., Bintz, J., Molejon, M. I., Velez, G., Lomberk, G. A., Neira, J. L., Urrutia, R. A., & Iovanna, J. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25022 · Cited by 26 · cited 1×
“Chemotherapeutic drugs such as oxaliplatin can induce TP53 as well as NUPR1L expression [166].”
BackgroundYang, S. T., Tang, M., Chen, W., Wang, Z., & Wang, S.-L. (2020) · Disease Markers · doi:10.1155/2020/7656031 · Cited by 25 · cited 1×
“High JAK2 expression is associated with a poor prognosis in PDAC [80].”
BackgroundThe p53/microRNA connection in gastrointestinal cancer
Rokavec, M., Li, H., Jiang, L., & Hermeking, H. (2014) · Dove Medical Press (Taylor and Francis Group) · Cited by 25
Duan, W., Qian, W., Zhou, C., Cao, J., Qin, T., Xiao, Y., Cheng, L., Li, J., Chen, K., Li, X., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6518 · Cited by 23 · cited 1×
“Metformin can also affect the invasive abilities of PDAC cells by blocking TGF-β signaling in the tumor microenvironment [194].”
BackgroundDey, S., Liu, S., Factora, T. D., Taleb, S., Riverahernandez, P., Udari, L., Zhong, X., Wan, J., & Kota, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-07135-2 · Cited by 23 · cited 22×
“miR-29a expression is regulated by TP53, and miR-29a in turn regulates TP53 expression by regulating MDM2 [38].”
BackgroundInfluentialWartenberg, M., Centeno, I., Haemmig, S., Vassella, E., Zlobec, I., Galván, J. A., Neuenschwander, M., Schlup, C., Gloor, B., Lugli, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.013 · Cited by 21 · cited 1×
“Decreased expression of PTEN has been observed in the PDAC stromal cells, which may be mediated by miR-21 [48].”
BackgroundThe NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma
Augello, G., Emma, M. R., Azzolina, A., Puleio, R., Condorelli, L., Cusimano, A., Giannitrapani, L., McCubrey, J. A., Iovanna, J., & Cervello, M. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.026 · Cited by 21 · cited 2×
“The effects of knock down (KD) of NUPR1 were examined in HCC cell lines [168,170,171].”
BackgroundSelf-citationSchipper, J., Westerhuis, J. J., Beddows, I., Madaj, Z. B., Monsma, D. J., Hostetter, G. H., Kiupel, M., Conejo-Garcia, J. R., & Sempere, L. F. (2020) · International Journal of Cancer · doi:10.1002/ijc.33041 · Cited by 20 · cited 1×
“miR-21 can mediate TGF-βmediated EMT and stemness [46].”
BackgroundLi, W., Jin, S., Hao, J., Shi, Y., Li, W., & Jiang, L. (2021) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0180 · Cited by 20 · cited 1×
“Metformin can influence the expression of the TP53/miR34a axis via activation of NAD-dependent deacetylase sirtuin-1 (SIRT1) [189].”
Backgroundp53 mutations define the chromatin landscape to confer drug tolerance in pancreatic cancer
Zampieri, C., Panatta, E., Corbo, V., Mauriello, A., Melino, G., & Amelio, I. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13161 · Cited by 19
Li, S., LI, X., Zhao, H., Gao, M., Wang, F., & Li, W. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4038 · Cited by 18 · cited 1×
“hsa-miR-125a-3p can regulate TP53 activity by inhibiting MDM2 expression, which results in stabilization of TP53 [99].”
BackgroundChen, Q., Wang, W., Chen, S., Chen, X., & Lin, Y. Q. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00266-9 · Cited by 18
Abrams, S. L., Duda, P., Akula, S. M., Steelman, L. S., Follo, M. L., Cocco, L., Ratti, S., Martelli, A. M., Montalto, G., Emma, M. R., et al. (2022) · Cells · doi:10.3390/cells11050794 · Cited by 16 · cited 1×
“Low doses of APR-246 reduced the IC50 concentrations of chemotherapeutic drugs, signal transduction inhibitors, BBR, or certain NAX compounds [203,204].”
BackgroundSelf-citationCremin, C., Howard, S. V., Le, L., Karsan, A., Schaeffer, D. F., Renouf, D. J., & Schrader, K. A. (2018) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-018-0088-y · Cited by 15
Akula, S. M., Candido, S., Abrams, S. L., Steelman, L. S., Lertpiriyapong, K., Cocco, L., Ramazzotti, G., Ratti, S., Follo, M. Y., Martelli, A. M., et al. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100672 · Cited by 13 · cited 1×
“The effects of BBRs and NAX compounds on PDAC have been recently described [199,200].”
BackgroundSelf-citationCandido, S., Abrams, S. L., Steelman, L. S., Lertpiriyapong, K., Martelli, A. M., Cocco, L., Ratti, S., Follo, M. Y., Murata, R. M., Rosalen, P. L., et al. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.03.002 · Cited by 12 · cited 1×
“A suboptimal concentration of nutlin-3a or BBR can increase the sensitivity to many of the chemotherapeutic drugs, targeted therapeutics and nutraceuticals in many cancer types [186,187].”
BackgroundSelf-citationAbrams, S. L., Akula, S. M., Steelman, L. S., Follo, M. L., Cocco, L., Ratti, S., Martelli, A. M., Libra, M., Falzone, L., Candido, S., et al. (2021) · Advances in Biological Regulation · doi:10.1016/j.jbior.2021.100840 · Cited by 10 · cited 1×
“Furthermore, the effects of nutlin-3 can be enhanced in PDAC cells by low doses of certain NAX compounds [201].”
BackgroundSelf-citationMcCubrey, J. A., Abrams, S. L., Steelman, L. S., Cocco, L., Ratti, S., Martelli, A. M., Lombardi, P., Gizak, A., & Duda, P. (2022) · Biomolecules · doi:10.3390/biom12020276 · Cited by 10 · cited 1×
“Low doses of APR-246 reduced the IC50 concentrations of chemotherapeutic drugs, signal transduction inhibitors, BBR, or certain NAX compounds [203,204].”
BackgroundSelf-citation
Cited by
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
“…in fl uencing mRNA degradation mechanisms [36]. variants, alter tumor microenvironment, promoting proliferation and chemotherapy resistance [34, Cases with TP53 mutations often co-occur These mutations, particularly gain-of-function (GOF) variants, alter the tumor microenvironment,…”
BackgroundTP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications
Wang, C., Tan, J. Y. M., Chitkara, N., & Bhatt, S. (2024) · Cancers · doi:10.3390/cancers16173069 · Cited by 68
“The cGAS-STING pathway is a critical mechanism of the innate immune system that detects cytosolic DNA, a signal often associated with viral infections or cellular damage [14,61].”
BackgroundAkter, K., Gul, K., & Mumtaz, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090716 · Cited by 74
“Extensive research indicates that nonfunctional mutated p53 sig-Curr nificantly contributes to tumor initiation and progression, correlating with poor clinical outcomes, reduced survival rates, unfavorable prognosis, and chemotherapy resistance in oncology patients [80–82].”
Zhang, C.-Y., Liu, S., & Yang, M. J. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i48.6827 · Cited by 40
TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress
Zhu, K., Su, F., Yang, J., Xiao, R., Wu, R.-Y., Cao, M.-Y., Ling, X., & Zhang, T. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09097-7 · Cited by 41
Metadata
- Authors
- McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M.
- Affiliations
- East Carolina University (US)
- University of Bologna (IT)
- Institute for Biomedical Research and Innovation (IT)
- Corresponding author
- McCubrey, James A.
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-07-09
- Volume
- 11
- Issue
- 14
- Pages
- 2155
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9318640
- OpenAlex
- W4285014119
- Cited by
- 49
- References
- 210
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 17 · 2023: 3 · 2022: 4
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- East Carolina University Grant (#111104, #111110-668715-0000)
- Fondazione del Monte di Bologna e Ravenna Research grant (#111104, #111110-668715-0000)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- TP53 mutation, microRNA, pancreatic ductal adenocarcinoma, tumor microenvironment, desmoplasia, immune response, tumor progression, gain-of-function mutations, chemoresistance
- MeSH terms
- Humans, Immunity, Mutation, Pancreatic Neoplasms, Tumor Suppressor Protein p53, Carcinoma, Pancreatic Ductal, MicroRNAs, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.